Access the full text.
Sign up today, get DeepDyve free for 14 days.
Oral therapy for erectile dysfunction with type-5 phosphodiesterase (PDE5) inhibitors has revolutionized treatment. This review presents a comprehensive update on PDE5 inhibitors and covers areas including erectile physiology, pharmacology, dosing and side effects. In addition, the use of these drugs in certain clinical situations including cardiovascular disease, as well as a discussion of rare adverse events, daily dosing, use of these drugs for the treatment of lower urinary tract systems, recreational use, novel uses for PDE5 inhibitors, and strategies for treatment failures are covered in detail. Because of the widespread use of PDE5 inhibitors for the treatment of erectile dysfunction, a comprehensive under-standing of these issues by health-care providers is necessary to ensure safe and effective prescribing practices and to improve patient satisfaction and quality of life.
Current Urology – Karger
Published: Jan 1, 2009
Keywords: Erectile dysfunction; Phosphodiesterase inhibitors
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.